NASDAQ:NEUP Neuphoria Therapeutics Inc. - Common Stock (NEUP) Stock Price, News & Analysis $5.05 +0.05 (+1.00%) As of 05/2/2025 03:24 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock About Neuphoria Therapeutics Inc. - Common Stock Stock (NASDAQ:NEUP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NEUP alerts:Sign Up Key Stats Today's Range$4.93▼$5.2550-Day Range$4.64▼$5.8052-Week Range$2.12▼$15.24Volume9,423 shsAverage Volume416,957 shsMarket Capitalization$8.87 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingBuy Company OverviewNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Read More… Neuphoria Therapeutics Inc. - Common Stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreNEUP MarketRank™: Neuphoria Therapeutics Inc. - Common Stock scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNeuphoria Therapeutics Inc. - Common Stock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuphoria Therapeutics Inc. - Common Stock has only been the subject of 1 research reports in the past 90 days.Read more about Neuphoria Therapeutics Inc. - Common Stock's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Neuphoria Therapeutics Inc. - Common Stock are expected to decrease in the coming year, from ($1.56) to ($1.85) per share.Price to Book Value per Share RatioNeuphoria Therapeutics Inc. - Common Stock has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NEUP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuphoria Therapeutics Inc. - Common Stock does not currently pay a dividend.Dividend GrowthNeuphoria Therapeutics Inc. - Common Stock does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NEUP. News and Social Media2.7 / 5News SentimentN/A News SentimentNeuphoria Therapeutics Inc. - Common Stock has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neuphoria Therapeutics Inc. - Common Stock insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Neuphoria Therapeutics Inc. - Common Stock is held by insiders.Percentage Held by InstitutionsOnly 15.90% of the stock of Neuphoria Therapeutics Inc. - Common Stock is held by institutions.Read more about Neuphoria Therapeutics Inc. - Common Stock's insider trading history. Receive NEUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuphoria Therapeutics Inc. - Common Stock and its competitors with MarketBeat's FREE daily newsletter. Email Address NEUP Stock News HeadlinesNeuphoria Therapeutics provides review of 2024, highlights 2025 plansApril 16, 2025 | markets.businessinsider.comNeuphoria Provides a Review of 2024 and Highlights 2025 PlansApril 15, 2025 | globenewswire.comU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost 80% of their wealth in real terms. But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch.May 3, 2025 | Stansberry Research (Ad)Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025March 3, 2025 | globenewswire.comNeuphoria Therapeutics Inc. to Receive $15M Milestone Payment from MerckFebruary 12, 2025 | globenewswire.comSee More Headlines NEUP Stock Analysis - Frequently Asked Questions How have NEUP shares performed this year? Neuphoria Therapeutics Inc. - Common Stock's stock was trading at $3.20 at the start of the year. Since then, NEUP stock has increased by 57.8% and is now trading at $5.05. View the best growth stocks for 2025 here. How were Neuphoria Therapeutics Inc. - Common Stock's earnings last quarter? Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) issued its earnings results on Friday, February, 14th. The company reported ($1.23) earnings per share for the quarter, beating analysts' consensus estimates of ($2.01) by $0.78. The business earned $660 billion during the quarter. Who are Neuphoria Therapeutics Inc. - Common Stock's major shareholders? Top institutional investors of Neuphoria Therapeutics Inc. - Common Stock include Cyndeo Wealth Partners LLC (0.57%). How do I buy shares of Neuphoria Therapeutics Inc. - Common Stock? Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/14/2025Today5/02/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NEUP Previous SymbolNASDAQ:NEUP CIK1191070 Webwww.bionomics.com.au Phone61-8-8150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+315.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.06 Quick Ratio3.30 Sales & Book Value Annual Sales$662,715.00 Price / Sales13.39 Cash FlowN/A Price / Cash FlowN/A Book Value$7.82 per share Price / Book0.65Miscellaneous Outstanding Shares1,757,000Free Float1,745,000Market Cap$8.87 million OptionableN/A Beta0.25 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:NEUP) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. - Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics Inc. - Common Stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.